NiKem Research has received, from the Italian Ministry of Health, GLP certification of its bioanalysis facilities to further extend its drug discovery service capabilities. With this certification NiKem will be able to offer bioanalysis as a GLP service to support clients preclinical PK and toxicology studies.
The company’s new capability is likely to allow to analyse biological samples from all preclinical species, in particular to provide GLP method development, resolve clients analytical bottlenecks, to provide a complete preclinical PK and Toxicokinetic GLP service.
Giuseppe Giardina, managing director and CEO of NiKem, said: “This new product is an important step in NiKem’s continuing expansion of its high quality, cost effective services to support progression of our clients’ drug discovery programmes”.